Tech Center 1600 • Art Units: 1651
This examiner grants 70% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18332893 | DOSING REGIMEN | Non-Final OA | Halozyme, Inc. |
| 18628290 | Bile Acids and Use in Disease Treatment | Final Rejection | The Regents of the University of California |
| 18006382 | DEGRADABLE HOLLOW SHELL PARTICLES FOR HIGH-THROUGHPUT SCREENING AND SORTING OF CELLS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18024477 | PROBIOTIC TREATMENTS FOR PARKINSON'S DISEASE | Final Rejection | California Institute of Technology |
| 18371602 | Fremyella diplosiphon as a Nutritional Feed Supplement for Aquaculture | Non-Final OA | Morgan State University |
| 17754071 | COMPOSITIONS AND METHODS USING ADENOSYLCOBALAMIN | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18601318 | THERAPEUTIC AGENT FOR DISC HERNIATION | Non-Final OA | Seikagaku Corporation |
| 18268477 | IMPROVED RECEPTOR-BINDING DOMAIN OF BOTULINUM NEUROTOXIN A AND USES THEREOF | Non-Final OA | Children's Medical Center Corporation |
| 18311875 | PHOTOBIOCONVERSION OF ELECTROCATALYSIS-DERIVED FORMATE | Non-Final OA | Alliance for Sustainable Energy, LLC |
| 17252446 | SUBTILASE VARIANTS AND COMPOSITIONS COMPRISING SAME | Final Rejection | NOVOZYMES A/S |
| 18413541 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES AND DISORDERS | Final Rejection | RESEARCH DEVELOPMENT FOUNDATION |
| 18392662 | TREATMENT OF ACUTE HEART FAILURE USING NITROUS OXIDE AND CHRONIC HEART FAILURE USING BOTULINUM TOXIN | Non-Final OA | Penland Foundation |
| 18562841 | NOVEL BIOLOGICAL MARKERS IN THE DIAGNOSIS OF ENDOMETRIOSIS | Non-Final OA | YEDITEPE UNIVERSITESI |
| 18283114 | ANTHOCYANIN BIOPRODUCTION IN A CELL-FREE MANUFACTURING SYSTEM | Non-Final OA | DEBUT BIOTECHNOLOGY, INC. |
| 18119991 | CYANOBACTERIA SUPPRESSION COMPOSITION AND METHOD OF USE | Non-Final OA | U.S. Environmental Protection Agency |
| 17640720 | TREATMENT OF TUMORS BY A COMBINATION OF AN ONCOLYTIC ADENOVIRUS, A CDK4/6 INHIBITOR AND A FURTHER THERAPEUTICALLY ACTIVE AGENT | Final Rejection | KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN |
| 17923296 | COMPOSITIONS COMPRISING ENZYMES AND PROBIOTICS, AND METHODS FOR PREVENTING OR TREATING MACULAR DEGENERATION | Final Rejection | GenoFocus, Inc. |
| 17947861 | METHODS FOR DISEASE ASSESSMENT USING DRAIN FLUID | Final Rejection | THE WASHINGTON UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy